drugset / Trial / NCT05170334
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
Phase 2
Active not recruiting
7 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Acrotech Biopharma Inc. · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.
Timeline
- Start
- 2021-12-15
- Primary completion
- 2025-12-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Binimetinib | Small molecule | 45 mg | Oral |